Histidine and Immunotherapy Response in Colorectal Cancer
ConditionColorectal Cancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorJing-yuan Fang, MD, Ph. D
About this trial
This observational study aims to investigate the role of histidine and its transporter SLC15A3 in modulating the sensitivity of colorectal cancer to immunotherapy. By analyzing the expression of SLC15A3 in tumor/normal colonic tissues from patients with colorectal cancer and assessing serum histidine metabolic levels, the study seeks to identify potential targets associated with therapeutic resistance and explore possible intervention strategies to improve immune checkpoint blockade treatment efficacy.
Eligibility criteria
Qualifiers
Participants aged ≥18 years and ≤100 years.
Patients pathologically diagnosed with colorectal cancer based on colonoscopy or surgical specimens and biopsy examination; or patients who previously received PD-1 monoclonal antibody immunotherapy for colorectal cancer.
Disqualifiers
Age <18 years.
Presence of poorly controlled metabolic diseases, including hypertension, diabetes mellitus, hyperlipidemia, hyperuricemia, or hyperthyroidism.
Presence of other severe gastrointestinal diseases, including inflammatory bowel disease, ischemic bowel disease, familial adenomatous polyposis, liver cirrhosis, MUTYH-associated polyposis (MAP), Lynch syndrome (LS), or Peutz-Jeghers syndrome (PJS).
History of other malignant tumors, or pathological diagnosis of colorectal inflammatory polyps, hyperplastic polyps, neuroendocrine tumors, neuroendocrine carcinoma, or mixed neuroendocrine-non-neuroendocrine neoplasms.
Trial design
Treatments tested in this trial
- Immunohistochemistry or immunofluorescence
- Serum metabolomic analysis or ELISA
- Flow cytometry
Treatment groups
150 Participants
are divided into 3 treatment groupsLocations
Sponsors and collaborators
Jing-yuan Fang, MD, Ph. D
Lead sponsor
Shanghai Jiao Tong University School of Medicine
Sponsor institution
Source ClinicalTrials.gov